Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
The purpose of this study is to determine whether high dose statin therapy in patients with
 aspirin mono antiplatelet therapy who had received drug-eluting stent (DES) previously and
 were free of the adverse cardiac events during the first 12 months could be superior over
 pravastatin therapy in the prevention of late adverse cardiac and cerebrovascular events
 during the additional 12 months.

 Study Design.
Objective: To determine whether high dose statin therapy in patients with aspirin mono
 antiplatelet therapy who had received drug-eluting stent (DES) previously and were free of
 the adverse cardiac events during the first 12 months could be superior over pravastatin
 therapy in the prevention of late adverse cardiac and cerebrovascular events during the
 additional 12 months.

 Study Design

 -  Prospective, randomized, multi-center study of each 1000 subjects enrolled.

 -  Eligible subjects will be randomized 1:1 to a) atorvastatin 40 mg (n=1000) vs. b)
 pravastatin 20 mg/day (n=1000). All subjects will be followed for 1 year after
 randomization. Additional long-term follow-up (2- or 3-year) will be preceded in the
 next plan after 1-year study period.

 -  Subjects with coronary artery diseases who meet all inclusion and exclusion criteria
 will be included Clinical and laboratory follow-up should be performed.
Inclusion Criteria:

 1. Patients who had previously received DES at least 12 months(±2month) ago

 2. Patients who were free of death, MI, stroke, repeat revascularization, or ST within
 first 12 months after DES implantation

 3. Patients with mono antiplatelet therapy with only aspirin after

 4. Age 20 years of older

 5. Patients with signed informed consent

 Exclusion Criteria:

 1. History of DES or BMS implantation within 10 months

 2. Patients who required the continuing dual antiplatelet therapy or additional other
 types of antithrombotics or antiplatelets such as cilostazol or ticlopidine, etc
 besides aspirin after DES implantation

 3. Patients who could not be prescribed aspirin or statins due to contraindication or
 severe side effects

 4. Pregnant women or women with potential childbearing

 5. Life expectancy ≤ 2 year